

# Index

---

- acetazolamide 148, 149
- N*-acetylcysteine 123, 147
- N*-acetyl-galactosamine 125
- N*-acetylglucosamine 125
- acetylsalicylic acid *see* aspirin
- acid, defence against 230–1
- acid inhibitors 229
- acyl hydrolase 193
- adaptive cytoprotection 65
- admission rates, England and Wales 1958–62, 1978–82 96 (table)
- AGEPC *see* platelet-activating factor
- albumin 213
- alcohol consumption 23
- alcoholic gastritis 155
- allopurinol 85, 219
- aluminium ions 156–7
- aminopyrine clearance 213
- Antepsin (sucralfate) 112, 140, 156, 227–8
- anti-oxidant compounds 85
- anti-platelet serum 196
- anti-ulcer agents 140, 156–7; *see also* drugs
- antroduodenal coordination 73
- antrum 73, 74 (fig)
- arachidonic acid 151
  - cyclo-oxygenase products 196
  - lipoyxygenase products 196
  - metabolism 183, 184 (fig)
- arthritis, dyspepsia associated 96
- aspirin (acetylsalicylic acid) 23, 84
  - absorption 86
  - anti-platelet effect 90
  - enteric-coated 87
  - gastric bicarbonate secretion inhibition 155
  - gastric mucosa exposed to 213
  - gastro-intestinal reactions 88 (table)
    - bleeding 90–4
    - death 88 (table)
  - mucosal damage damage
    - reduction/inhibition 85
  - mucus affected by 133
  - paracetamol compared 93, 97
  - prostacyclin generation inhibition 185
  - prostaglandin generation inhibition 184–5
    - unbuffered 87
    - see also* non-steroidal anti-inflammatory drugs
  - azapropazone 86, 88 (table)
- bacillary dysentery 45
- bacteria 101
  - historical aspects 101–2
  - on luminal surface of epithelial cells 103–4
- barrier breakers 164
- benoxaprofen 85, 88 (table)
- benzalkonium 153
- 1-benzylimidazole 189, 190, 191 (fig)
- bicarbonate secretion 145–62
  - duodenal 148–9, 151–2
    - human 153
  - gastric 147–8, 149 (fig), 150–1
    - duodenal ulcer patient 155
    - human 152–3
    - neural regulation 150–1
  - history 146–7
  - in disease 155
  - peptic ulcer patient 155
  - stress effect 155
  - therapeutic manipulation 156–7
- bile acids
  - gastric mucosa damage 64–5
  - intraagastric concentrations
    - fasting studies 56
    - post-prandial 56, 57 (table)
- bile diversion (dog) 64
- bile salt injury 62
- Biogastrone (carbenoxolone) 156, 157, 226–7
- birth-cohort phenomenon 6–13
- bismuth 156
  - salts 112, 227
- blue-collar workers 13, 14 (fig)
- BN-52021 199
- bromsulphthalein 52
- brucellosis 48
- BW 755C 185 (fig), 186 (table), 186, 187, 191–2
  - pre-treatment of platelet-activating factor induced damage 196, 197 (fig)
- calcium 150

## ADVANCES IN PEPTIC ULCER PATHOGENESIS

- Campylobacter jejuni* 108 (table)  
*Campylobacter*-like organisms 104  
 gastric, type-2 109  
*Campylobacter pylori* (*C. pyloridis*) 104–14, 134  
 acute gastrointestinal disturbance due to 112  
 antibody 110  
 bacteriology 107–9  
 biotyping, *C. jejuni* compared 108 (table)  
 drug susceptibilities 108, 109 (table), 112  
 duodenal infection 107  
 electron microscopy 110  
 enzyme-linked immunosorbent assay (ELISA) 109, 110  
 ferret as animal model 113  
 geographical distribution 105 (table)  
 histological identification 105–7  
 immunology 109–10  
 pathogenicity 111–13  
 sensitivity to bismuth salts 227  
 urease activity 108, 113  
*Candida albicans* 103  
 Capper's pyloric regurgitation test 52, 55 (table)  
 Carafate (sucralfate) 112, 140, 156, 227–8  
 carbachol 150, 151, 153  
 carbenoxolone (Biogastrone; Duogastrone) 156, 157, 226–7  
 carbomer 140  
 carbonic anhydrase 207–8  
 Caved-S 227  
 cerebrovascular disease relationship 19, 20 (fig)  
 cholecystokinin (CCK) 54–5, 72, 150  
 cholelithiasis *see* gallstones  
 cholera 48, 101  
 cholestyramine 62  
 cimetidine 46 (fig), 156, 196  
 antisecretory assessment 42, 45 (fig)  
 antral prostanoid production 188–9  
 cisapride 75  
 colloidal bismuth (De-Nol) 140, 227, 229–30  
 corticosteroids 94  
 CV-3988 198, 199 (table)  
 cyclo-oxygenase enzyme 183, 184 (fig)  
 cyclo-oxygenase inhibitors 184–6  
 'cytoprotection' 164  
 cyclic AMP 151  
 cyclic GMP 150, 151  
 Cytote *see* misoprostil
- death rate 2–5  
 deglycyrrhized liquid products 227  
 De-Nol (colloidal bismuth) 140, 227, 229–30  
 dexamethasone 196  
 diclofenac 88 (table)  
 16, 16-dimethyl-prostaglandin E<sub>2</sub> *see* isoprostil
- dimethylsulphoxide 219  
 2,4-dinitrophenol 148  
*Diphyllobothrium latum* infestation 48  
 disability pensions 15–16  
 domperidone 75  
 drug(s) 140, 156–7, 226–35  
 acid inhibitors 229  
 defence against acid/pepsin 230  
 enhancing protective mechanisms 231–2  
 enhancing repair processes 233–4  
 improving current agents 229–30  
 prospects 234–5  
*see also specific agents*  
 drug-induced mucosal damage 81–100  
 clinical trials 82–3  
 experimental data  
 animal experiments 81–2  
 human experiments 82  
 tissue experiments 82  
 human experiments 86–7  
 non-steroidal anti-inflammatory drugs *see* non-steroidal anti-inflammatory drugs  
 pharmaco-epidemiological evidence 83–4  
 predisposing factors 85–6  
 eicosanoid synthesis 86  
 microbial 86  
 pharmacokinetic 86  
 duodenal ulcer, abnormal duodenogastric reflux 58  
 duodenitis 107, 113  
 duodenogastric reflux 51–65  
 assessment methods 51–3  
 bile acids etc. concentrations 53  
 marker substances 52  
 non-invasive 53  
 technique 54–5  
 bile acid reflux 59 (fig), 60 (fig)  
 characterization 52 (table)  
 experimental studies 60–2  
 bile salt injury 62  
 exposure to pancreatic/biliary secretion 61–2  
 in: duodenal ulcer 58  
 gallbladder disease 58  
 gastric ulcer 55–7  
 health 53–4  
 oesophagitis 58–9  
 significance in gastric ulcer 63–5  
 mucosal factors 64  
 slow gastric emptying 63–4  
 duodenum  
 contraction propagation direction 74–5  
 metaplastic gastric epithelium 21, 107, 113  
 Duogastrone (carbenoxolone) 156, 157, 226–7  
 dyspepsia, flatulent 58

## INDEX

- eicosanoids 183–4
  - synthesis 86
- endoperoxides 184 (table)
- endotoxin (septic) shock 198–9
- energy expenditure 13–18
- enprostil (Gardin) 228
- epidemiology 1–31
- epidermal growth factor (urogastrone) 233
- epithelial restitution, rapid 165–78
  - epithelial necrosis 165–6
  - exfoliation 166–8
  - plasma shedding associated 177
  - protection by exfoliated mucoid layer 176–7
  - re-epithelialization by cellular migration 168–76
  - repeated mucosal challenge 176
- ethanol 155
  - absolute, effect on gastric mucosa 164, 165–76, 213–14
  - microvascular changes 211–13
  - mucus role 137–9, 176–7
  - stressed/non-stressed rats 188
  - absorption across gastric mucosa 211
  - low concentration effect 194
- Evans Blue 213
- exercise effect on acid secretion 17–18
- famotidine 46 (fig)
- fenamates 97
- ferrets 113
- fibre, dietary 23
- flurbiprofen 97, 184, 185 (fig), 186 (table)
- free-radical scavengers 85
- fucose 125
- fungi 103
- furazolidine 112
- galactose 125
  - gallbladder disease, duodenogastric reflux 58
- gallstones 58
  - gastric mucosal atrophy associated 65
- Gardin (enprostil) 228
- gastric acid role 45–8
- gastric acid secretion
  - beverages stimulated 34 (table), 35–6
  - circadian rhythm 42
  - food-stimulated 33–6
  - Fordtran and Walsh's test 33
  - 24-hour 36–8
    - electronic measurement 41
  - 24-hour intragastric acidity 38–41
    - antisecretory drugs assessment 42–5
    - meal-related intervals 47 (fig)
- gastric cancer
  - cerebrovascular disease relationship 19, 20 (fig)
  - post-partial gastrectomy 25
- gastric circulation 205–9; *see also* gastric microvasculature
- gastric inhibitory peptide (GIP) 150, 151
- gastric microvasculature 205–23
  - arterio-venous shunts 207
  - changes in mucosal injury 211–14
  - defence mechanisms 209–11
    - clearance of intra-mucosal irritants 211
    - maintenance of acid-base status 209–10
    - metabolic support 211
  - mucosal disease 218–19
  - protection of mucosa 214–18
    - cytoprotection in isolated mucosa? 218
    - cytoprotection or vasoprotection? 214–15
    - cytoprotective agents 216–18
    - cytoprotective prostaglandins 215, 216
- gastric mucosa
  - absolute ethanol effect *see under* ethanol
  - atrophic 65
  - autodigestion resistance 225–6
  - barrier 163
  - bile acid damage 64–5
  - blood flow 213
  - defence mechanisms 209, 225–37
    - against acid/pepsin 230–1
  - epithelial restitution *see* epithelial restitution
  - factors in acute gastric ulcer 64
  - intestinalized 21, 107, 113
  - ischaemia 64, 218–19
  - linear haemorrhagic lesions 164
  - luminally-induced damage 164
  - normal (rat) 166 (fig), 167 (fig)
  - permeability increase 163
  - protective mechanisms enhancement 231–3
  - repair mechanisms 225–37
    - enhancement 233–4
  - restitution 231
  - steep ionic gradients across 163
- gastric ulcer
  - acute 64
  - mucosal ischaemia 218–19
  - solid emptying 73
  - stress associated 61, 62, 219
- gastrin 150
  - 24-hour plasma concentration 42, 44 (fig)
- gastritis 18
  - alcoholic 155
  - mucosal susceptibility to ulcer 21
- geographic variation 1, 2–6
- giardiasis 48
- glucagon, pancreatic 150, 151
- glucocorticoid anti-inflammatory agents 196
- hiatus hernia 60

## ADVANCES IN PEPTIC ULCER PATHOGENESIS

- histamine 135, 150, 196  
 H<sub>2</sub>-receptor antagonists 46 (figs), 85  
     bed-time medication 48  
     *C. pylori* investigations 112  
     ulcer healing promoted 64  
 hydroperoxyeicosatetraenoic acid 191  
 hyperacidity 225  
  
 ibuprofen 88 (table)  
 indocyanine green 52  
 indomethacin 81, 84, 87  
     absorption 86  
     action on PAF mucosal damage 197 (fig)  
     colitis due to 97  
     duodenal bicarbonate secretion inhibition 151, 155  
     enterohepatic circulation 86  
     gastric bicarbonate secretion inhibition 150, 155  
     gastrointestinal reactions 88 (table)  
         deaths 88 (table)  
     intravenous/oral compared 86  
     osmotically-released (Osmosin) 97  
     prostaglandin generation inhibition 184–5, 186 (table)  
         suppositories, rectal ulceration due to 97  
 intellectuals 15  
 isoprenaline 150  
  
 Japanese, Hawaiian 19  
  
 ketoprofen 88 (table), 184, 186 (table)  
  
 leukotriene(s) 184  
 leukotriene B<sub>4</sub> 191, 192  
 lipid, high dietary intake 85  
 lipoxygenase enzyme 183, 184 (fig)  
 lipoxygenase products 191–2  
 lower bowel disease 97  
 Lundh balanced meal 55  
 lysolecithin 62–3, 65  
 lyso-platelet-activating factor 192, 194  
  
 male/female ratio 25  
 married women 16  
 meclofenamate 186 (table)  
 mepyramine 196, 197 (fig)  
 mercaptoethanol 123  
 metoclopramide 75  
 metronidazol 112  
 migrant workers 15, 17  
 migrating myoelectrical complex 56, 57  
 misoprostil (Cytote; 16,16-dimethyl-prostaglandin E<sub>2</sub>) 215, 228  
     bicarbonate secretion stimulated 153, 156  
     *C. pylori* colorization effect 112  
     gastritis effect 112  
     mucus gel thickness 140  
 Monastral Blue B 213  
 mortality variation 2–5  
 mucus 121–44, 154  
     adherent gel 122–4  
     anti-oxidant behaviour 154  
     aspirin effect 133  
     barrier impairment in peptic ulcer disease 132–4  
     composition 123–4  
     ethanol-induced mucosal damage, role in 137–9  
     gastritis effect 133  
     'gel-like'/liquid-like' properties ratio 130  
     glycoproteins 124–8  
         ABH antigenic activity 125  
         amino acids 127  
         carbohydrate composition 132, 134  
         mucus gel formation 128–32  
         proline content 127  
         structure 128–32  
         sugars 125  
     *in vivo* 121–2  
     luminal 122, 123  
     mucosal protection against acid 134, 136 (fig)  
     mucosal protection against pepsin 135–7  
     phospholipid monolayer 124, 154  
     small intestine gel 124  
     ulcer therapy 139  
 mucus–bicarbonate barrier 135, 145, 147 (fig), 154–5  
     *see also* bicarbonate secretion  
  
 naproxen 88 (table), 185 (fig), 186 (table)  
 natural clays 140  
 NDGA 186 (table)  
 neurotensin 151  
 non-aspirin, non-steroidal anti-inflammatory drugs 94–7  
     lower bowel disease 97  
     oesophageal stricture 96  
     ulcerative colitis 97  
     ulcer complications 94–5  
     ulcer occurrence 96–7  
 non-steroidal anti-inflammatory drugs (NSAIDs) 23, 81  
     absorption across gastric mucosa 211  
     acute gastric lesions due to 86–7  
     adverse reactions surveillance 87–94  
         case–control studies 89–90  
         case series 89  
         clinical trial data 88–94  
         spontaneous reports 87–8

## INDEX

- disruption of pH gradient 155
- gastric damage 185 (fig), 187
- inflammatory exudate inhibition 185 (table)
- inhibition of bicarbonate secretion 155
- laxative actions 97
- mucosal damage 84–7
  - experimental data 84–5
- prostaglandin formation inhibition 185 (table)
- side-effects 86–7
- noradrenaline 150, 196
  
- occupational workload 13–18
- oesophageal stricture 96
- oesophagitis, duodenogastric reflux 58–60
- OKY-1581 190
- omeprazole 43, 46 (fig), 47 (fig), 156, 229
- opiates 151
- Osmosin 97
- oxmetidine 46 (fig)
- oxyphenbutazone 87, 88 (table)
  
- pancreatic juice, diversion (dog) 64
- papain 123
- paracetamol 92, 186–7
  - aspirin compared 93
  - 'barrier-breaking' activity 187
- pepsin 123
  - defence against 230–1
  - mucosal protection against, mucus role 135–7
- pepsin-1 133–4
- pepsin-3 133
- peptides, large 234
- pernicious anaemia, 24-hour intragastric acidity 40–1
- pharmacological antacid 232
- phentolamine 196, 197 (fig)
- phenylbutazone 87
  - gastrointestinal reactions 88 (table)
- phospholipase A<sub>2</sub> 63, 65, 192, 198
- 'pH stat' system 148
- physicians, peptic ulcer disease in 11
- pirenzepine 156
- piroxicam 88 (table)
- plasma shedding 177
- plasma skimming 216–18
- platelet-activating factor (PAF; PAF-acether; AGEPC) 184, 192–9
  - in: gastrointestinal damage 194–6
  - septic shock 198–9
  - mediator role in PAF-induced damage 196, 197 (fig)
  - neutrophil aggregation 196
  - platelet aggregation 196
- polyacrylates 140
- prednisolone 196
  
- prokinetic drugs 75
- prostacyclin (PGI<sub>2</sub>) 215, 216, 217 (fig)
- prostaglandins 84–5, 151, 154, 228
  - anti-ulcerogens effect 196
  - bicarbonate secretion stimulation 150, 151, 153
  - cytoprotective 215
  - E series 147, 150, 196, 215
  - F series 150, 215
  - mucosal pretreatment with 164
  - mucosal protection 155
  - mucus-secreting cell stimulation 122, 139–40
  - synthesis interference 87
  - 'tone' 153
- prostanoids 183
  - cyclo-oxygenase inhibitors effect on metabolism 184–6
  - gastric damage related 186–7
  - mucosal integrity maintenance 187–8
  - pathogenesis of peptic ulcer disease 188–9
- protective mechanisms enhancement 231–3
- PTH 150
- pseudomembranous colitis 48
- Pseudomonas aeruginosa* 104
- pylorus 66–73
  - anatomy 66–7
  - 'contractions' 68, 72 (fig)
  - defect in gastric ulcer disease 71
  - impedance studies 69–71
  - neural control 67
  - physiology 67
  - pressure within canal 67–8, 71
  - duodenal ulcer patients 71
- Pyrogastrone 112
  
- ranitidine 46 (figs), 47 (fig)
- repair processes enhancement 231–3
- restitution 231
- rheumatoid arthritis, peptic ulcer associated 89, 96
- RO-193704 199
- Roux-en-Y diversion 61, 62
  
- Salmonella typhosa*, lipopolysaccharide from 198
- salmonellosis 45, 101
- salt
  - consumption 18–21, 24
  - interaction with workload 24 (fig)
  - urinary excretion 19
- secretin 150
- serine 127
- shock
  - haemorrhagic 216
  - septic (endotoxin) 198–9
- sialic acid 125

## ADVANCES IN PEPTIC ULCER PATHOGENESIS

- slow reacting substance of anaphylaxis (SRS-A) 191
- smecta 140
- smoking 21-2
- sodium acetylsalicylate 84
- sodium chloride *see* salt
- sodium salicylate 185 (fig), 186, 187
- sodium taurocholate 61, 150, 194-5
- Solon (sulfacone) 230
- spiral organisms 103-4
- standardized mortality ratio (SMR) 2
  - duodenal ulcer 3, 4 (fig)
  - gastric ulcer 3, 4 (fig)
- Staphylococcus pyogenes* 102
- status occupations 15
- stomach *see* entries under gastric
- streptococci 102
  - alpha- 102
  - non-haemolytic 102
- stress ulceration 61, 62, 219
- Strongyloides stercoralis* infestation 48
- substance P 151
- sucalfate (Antepsin; Carafate) 112, 140, 156, 227-8
- sufalcone (Solon) 230
- sulphasalazine 97
- sulphated carbohydrates 140
- sunburn 65
- superoxide dismutase 219
- tachyphylaxis 232
- <sup>99m</sup>technetium iminodiacetic acid (HIDA) 52, 53-4
  - gallbladder disease 58, 59 (fig)
- temporal variation 6-13
- threonine 127
- thromboxane A<sub>2</sub> 184, 189-91
- tiaprofenic acid 81
- transmucosal potential difference 86
- 11,16,16-trimethyl-prostaglandin E<sub>2</sub> 156
- tripotassium dicitrate bismuthate 156
- typhoid fever 45
- U-46619 189, 190
- ulcerative colitis 97
- unified theory of peptic ulcer disease 24-5
- urea breath test [<sup>13</sup>C] 108
- urease 108
- urogastrone (epidermal growth factor) 233
- vagotomy
  - luminal mucin glycoprotein in vagotomised patient 123
  - partial devascularisation of stomach due to 206
  - pepsin in vagotomised patient 123
  - ulcer healing promoted 64
- wound healing 233
- Zoladex 234